Allogene Therapeutics, Inc.: retained earnings or deficit
Retained earnings or deficit for Allogene Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Allogene Therapeutics, Inc. financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | -2,010,709,000 | USD | 2026-03-12 | 10-K · 0001628280-26-017242 |
| At date | 2024-12-31 | -1,819,823,000 | USD | 2026-03-12 | 10-K · 0001628280-26-017242 |
| At date | 2023-12-31 | -1,562,233,000 | USD | 2025-03-13 | 10-K · 0001737287-25-000036 |
| At date | 2023-09-30 | -1,476,455,000 | USD | 2024-03-14 | 10-K · 0001737287-24-000021 |
| At date | 2023-06-30 | -1,414,168,000 | USD | 2024-03-14 | 10-K · 0001737287-24-000021 |
| At date | 2023-03-31 | -1,334,936,000 | USD | 2024-03-14 | 10-K · 0001737287-24-000021 |
| At date | 2022-12-31 | -1,234,968,000 | USD | 2024-03-14 | 10-K · 0001737287-24-000021 |
| At date | 2022-09-30 | -1,137,693,000 | USD | 2024-03-14 | 10-K · 0001737287-24-000021 |
| At date | 2022-06-30 | -1,053,451,000 | USD | 2024-03-14 | 10-K · 0001737287-24-000021 |
| At date | 2022-03-31 | -973,161,000 | USD | 2024-03-14 | 10-K · 0001737287-24-000021 |
| At date | 2021-12-31 | -894,554,000 | USD | 2024-03-14 | 10-K · 0001737287-24-000021 |
| At date | 2020-12-31 | -712,503,000 | USD | 2024-03-14 | 10-K/A · 0001737287-24-000018 |
| At date | 2019-12-31 | -396,122,000 | USD | 2021-02-25 | 10-K · 0001737287-21-000009 |
| At date | 2018-12-31 | -211,528,000 | USD | 2020-02-27 | 10-K · 0001737287-20-000012 |
| At date | 2017-12-31 | -23,000 | USD | 2019-03-08 | 10-K · 0001564590-19-006991 |
Related financial histories
- Allogene Therapeutics, Inc.: total assets
- Allogene Therapeutics, Inc.: total liabilities
- Allogene Therapeutics, Inc.: stockholders equity
- Allogene Therapeutics, Inc.: cash and cash equivalents
- Allogene Therapeutics, Inc.: net income or loss
- Allogene Therapeutics, Inc.: operating cash flow
- Allogene Therapeutics, Inc.: capital expenditure payments
- Allogene Therapeutics, Inc.: contract revenue excluding tax
- Allogene Therapeutics, Inc.: financing cash flow
- Allogene Therapeutics, Inc.: investing cash flow
- Allogene Therapeutics, Inc.: basic weighted-average shares
- Allogene Therapeutics, Inc.: diluted weighted-average shares
- Allogene Therapeutics, Inc.: basic earnings per share
- Allogene Therapeutics, Inc.: diluted earnings per share
- Allogene Therapeutics, Inc.: income tax expense or benefit
- Allogene Therapeutics, Inc.: net property, plant and equipment
- Allogene Therapeutics, Inc.: share-based compensation expense
- Allogene Therapeutics, Inc.: operating income or loss
- Allogene Therapeutics, Inc.: current assets
- Allogene Therapeutics, Inc.: interest expense
- Allogene Therapeutics, Inc.: current liabilities
- Allogene Therapeutics, Inc.: current accounts payable
- Allogene Therapeutics, Inc.: operating expenses
- Allogene Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Allogene Therapeutics, Inc. / CIK 0001737287
- Captured
- 2026-09-21T17:25:34.429Z
- SEC response SHA-256
72fd10b01924601ea6c5521bb9259a3cc61e2cf80754530b1d76b345fa61c5a8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001737287.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))